Data di Pubblicazione:
2020
Citazione:
Lactate dehydrogenase: an old enzyme reborn as a COVID-19 marker (and not only) / M. Panteghini. - In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. - ISSN 1434-6621. - (2020). [Epub ahead of print] [10.1515/cclm-2020-1062]
Abstract:
Background: Historically, the lactate dehydrogenase
(LDH) measurement was introduced into Laboratory Medicine
as component (together with creatine kinase (CK) and
aspartate aminotransferase) of the classical enzyme triad
employed for the diagnosis of myocardial infarction, which
was subsequently replaced by CK-MB, and more recently
by cardiac troponins. Afterwards, for many years, the
clinical application of serum LDH measurement has been
limited to the evaluation of anemias and to as a rough
prognostic tool for certain tumors.
Content: In the last few years, significant changes have
happened. First, the test has been confirmed as a robust
predictor of poor outcomes in many neoplastic conditions.
Furthermore, in the Revised International Staging System
adopted in the 2015 by the International Myeloma Working
Group, LDH acts as determinant of disease biology in differentiating myeloma stages. Finally, in the last few months, LDH is definitively reborn given its proven significant contribution in defining the COVID-19 severity.
Conclusions: This increased clinical role calls for an improvement of LDH assay standardization through the implementation of traceability of results of clinical samples to the available reference measurement system.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
clinical enzymology; lactate dehydrogenase; tumors; SARS-CoV-2 disease; standardization
Elenco autori:
M. Panteghini
Link alla scheda completa: